Immunotherapy and diabetes: A game of hide and seek?
Immune checkpoint inhibitors (ICIs) are an emerging type of cancer immunotherapy that uses the immune system to attack cancer cells. However, in some patients they cause the immune system to attack healthy cells, leading to autoimmune diseases. When pancreatic beta cells are attacked, this can lead to type 1 diabetes. In a case report published in Diabetes Care, researchers from Osaka University provide insight into this unintended consequence of ICIs.